Lamivudine and therapeutic vaccine evaluation in Senegalese patients with chronic hepatitis B infection

Trial Profile

Lamivudine and therapeutic vaccine evaluation in Senegalese patients with chronic hepatitis B infection

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Lamivudine (Primary) ; Hepatitis B vaccine recombinant
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms HEPADAK-2
  • Most Recent Events

    • 31 Mar 2008 Status change from recruiting to discontinued, due to poor patient recruitment, as reported by clinicaltrials.gov.
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top